asopharyngeal airway vs nasal cannula in EBUS
Phase 1
- Conditions
- Health Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecified
- Registration Number
- CTRI/2019/07/020043
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age less than or equal to 18 years
BMI less than 30
ASA physical Status I - III
Able to give informed consent
Planned for sedation
Exclusion Criteria
Age less than 18 years
Refusal or unable to consent
Trachea intubated or requiring intubation for procedure
Pregnant females
Active nasal bleeding
Nasal, nasopharyngeal or base of skull pathology
Patient with baseline saturation less than 92%
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients experiencing desaturation below 92% during the procedure.Timepoint: From administering sedation to the end of the procedure.
- Secondary Outcome Measures
Name Time Method 1.Lowest SpO2 during the procedure <br/ ><br>2.Number of hypoxic episodes (SpO2 below 92%) during the procedure in individual patients <br/ ><br>3.Duration of hypoxia during the procedure in seconds <br/ ><br>4.Any complications, including number of interruptions to procedure to allow anaesthetic intervention, arrhythmia, myocardial ischaemia and cardiac arrest. <br/ ><br>5.Number of patients requiring insertion of definitive airway <br/ ><br>6.Incidence of dryness of nasal mucosa, dry throat/irritation, retained secretionsTimepoint: Data will be collected at an interval of 5 minutes after start of the procedure if it is uneventful. Continuous monitoring for oxygen saturation and complications, if any, will be done in addition to the fixed 5 minutes interval.